Cover Image
市場調查報告書

胰臟癌:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析

Pancreatic cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365180
出版日期 內容資訊 英文 180 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
胰臟癌:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析 Pancreatic cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 180 Pages
簡介

本報告提供胰臟癌的已上市及臨床實驗中 (開發平台上)的治療藥相關分析,各產品的市場規模的估計值,目前治療選擇,及有未來潛力的產品,目前主要產品中有轉換學名藥可能性的東西,各開發中產品的功效、潛在的市場規模及限制等相關調查。

市場預測:胰臟癌

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義和分析方法
  • Abraxane (白蛋白結合Paclitaxel)
  • Momelotinib
  • Tarceva (erlotinib)
  • 一次調查技術

治療方法:胰臟癌

  • 摘要整理
  • 調查手法
  • 疾病定義與診斷方法
  • 患者的分類
  • 各國治療系統
  • 目前治療選擇
  • 處方的趨勢

流行病學:胰臟癌

  • 摘要整理
  • 資訊來源、分析方法
  • 市場預測
  • 流行病學者的見解
  • 分析的優勢與限制

已上市藥物:胰臟癌

  • 摘要整理
  • 產品概要
  • 產品簡介:Abraxane
  • 產品簡介:Onivyde
  • 產品簡介:TS-1
  • 產品簡介:Tarceva

開發中產品:胰臟癌

  • 摘要整理
  • 臨床實驗開發平台概要
  • 產品簡介 (最後階段):HyperAcute-Pancreas
  • 產品簡介 (最後階段):Lynparza
  • 產品簡介 (最後階段):多株抗體刺激藥
  • 產品簡介 (最後階段):Yttrium-90 clivatuzumab tetraxetan
  • 產品簡介 (最後階段):masitinib
  • 產品簡介 (最後階段):momelotinib

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5601

The prognosis of patients with pancreatic cancer remains poor; however, this clinical need will drive future market expansion and the development of several targeted therapies.

This report addresses the following questions:

  • What are the current treatment options for patients with pancreatic cancer in each therapeutic setting?
  • Which products will drive growth of the pancreatic cancer market during 2015-24?
  • Which brands will experience generic competition over the course of the forecast period and what impact will this have on the value of the overall pancreatic cancer market?
  • How do pipeline therapies compare in terms of their clinical and commercial attractiveness, and how are companies attempting to differentiate their products?
  • Which pipeline products will have a limited uptake in the pancreatic cancer market?

TABLE OF CONTENTS

FORECAST: PANCREATIC CANCER

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Abraxane (albumin-bound paclitaxel)
  • 5. Momelotinib
  • 6. Tarceva (erlotinib)
  • 7. Primary Research Methodology

TREATMENT: PANCREATIC CANCER

  • 8. Executive Summary
  • 9. Survey Methodology
  • 10. Disease Definition and Diagnosis
  • 11. Patient Segmentation
  • 12. Country Treatment Trees
  • 13. Current Treatment Options
  • 14. Prescribing Trends

EPIDEMIOLOGY: PANCREATIC CANCER

  • 15. Executive Summary
  • 16. Sources and Methodology
  • 17. Forecast
  • 18. Epidemiologist Insight
  • 19. Strengths and Limitations

MARKETED DRUGS: PANCREATIC CANCER

  • 20. Executive Summary
  • 21. Product Overview
  • 22. Product profile: Abraxane
  • 23. Product profile: Onivyde
  • 24. Product profile: TS-1
  • 25. Product profile: Tarceva

PIPELINE: PANCREATIC CANCER

  • 26. Executive Summary
  • 27. Clinical Pipeline Overview
  • 28. Product profile (late stage): HyperAcute-Pancreas
  • 29. Product profile (late stage): Lynparza
  • 30. Product profile (late stage): Polyclonal Antibody Stimulator
  • 31. Product profile (late stage): Yttrium-90 clivatuzumab tetraxetan
  • 32. Product profile (late stage): masitinib
  • 33. Product profile (late stage): momelotinib
Back to Top